OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor
Condition: Breast Cancer
Sponsor: Olema Pharmaceuticals, Inc.
Full Title
OP-1250-301: A Phase 3 Randomized, Open-label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2– Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy
Study Treatment
OP-1250 (palazestrant), an oral complete estrogen receptor antagonist (CERAN)
Eligibility/Info
For patients with metastatic ER+, HER2- metastatic breast cancer previously treated with 1-2 prior lines of endocrine therapy which included a CDK4/6 inhibitor.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
